Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma With 6 Months Follow-up
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the efficacy of photodynamic therapy (PDT)in treatment of Basal cell carcinoma (BCC) and recurrence rate after 6 months.
| Condition | Intervention | Phase |
|---|---|---|
|
Basal Cell Carcinoma |
Radiation: photodynamic therapy |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
- response rate at the end of therapy protocol (regarding tumor diameter and/or pathologic examination) [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
- recurrence rate(regarding clinical and/or pathological examination) after 6 months of follow up [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
| Enrollment: | 28 |
| Study Start Date: | January 2008 |
| Study Completion Date: | August 2009 |
| Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: BCC, ALA-PDT
Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
|
Radiation: photodynamic therapy
5-ALA cream 20% topical administration + photodynamic therapy (red light) 120 j/cm2
Other Name: PDT 1200L Waldman Medizintechnik, Villengen; Schwenningen, Germany
|
Detailed Description:
Background and Aim:
Basal cell carcinoma (BCC) is the most common skin cancer .Photodynamic therapy _as a novel , non-invasive therapeutic approach _may be considered a valuable strategy. This study was designed with the aim of the evaluation of efficacy of PDT in treatment of BCC and recurrence rate after 6 months .
Materials and Methods:
This was a clinical trial which was done on 28 BCCs. Patients were treated with ALA-PDT monthly for 1-6 sessions and evaluated for clinical response,cosmetic results,recurrence rate and probable side effects.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically proven BCCs
Exclusion Criteria:
- Rodent ulcer
- Morphea type
- ANA +
- History of photosensitivity or photodermatosis or ingestion of phototoxic drugs during last month
- Pregnancy
- Breast feeding
- Age< 18
- History of another therapeutic intervention for bcc during last 6 months
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Zohreh Tehranchi-nia, assistant professor of dermatology |
| ClinicalTrials.gov Identifier: | NCT00988455 History of Changes |
| Other Study ID Numbers: | pdt bcc 2, zthr |
| Study First Received: | September 29, 2009 |
| Last Updated: | October 1, 2009 |
| Health Authority: | Iran: Ethics Committee |
Keywords provided by Shaheed Beheshti Medical University:
|
basal cell carcinoma photodynamic therapy photo chemotherapy basal cell epithelioma |
Additional relevant MeSH terms:
|
Carcinoma Carcinoma, Basal Cell Neoplasms, Glandular and Epithelial |
Neoplasms by Histologic Type Neoplasms Neoplasms, Basal Cell |
ClinicalTrials.gov processed this record on May 16, 2013